By the end of 2017, CTS has secured three source plasma partners and continues to seek additional partners in the plasma industry in order to continue to diversify CTS’s revenue stream.
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...
CTS Research Consortium was established to further CTS’s leadership in infectious disease research....
In August CTS begins source plasma testing as a new line of business to one of the largest plasma fr...
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...
In August, the CTS Tampa lab transitioned to the same laboratory information systems (LIS) as the Da...